Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis Stimulating Agents